0001104659-22-097870.txt : 20220906 0001104659-22-097870.hdr.sgml : 20220906 20220906163039 ACCESSION NUMBER: 0001104659-22-097870 CONFORMED SUBMISSION TYPE: 8-K/A PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20220906 ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20220906 DATE AS OF CHANGE: 20220906 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Synthetic Biologics, Inc. CENTRAL INDEX KEY: 0000894158 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 133808303 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K/A SEC ACT: 1934 Act SEC FILE NUMBER: 001-12584 FILM NUMBER: 221228618 BUSINESS ADDRESS: STREET 1: 9605 MEDICAL CENTER DRIVE STREET 2: SUITE 270 CITY: ROCKVILLE STATE: MD ZIP: 20850 BUSINESS PHONE: (734) 332-7800 MAIL ADDRESS: STREET 1: 9605 MEDICAL CENTER DRIVE STREET 2: SUITE 270 CITY: ROCKVILLE STATE: MD ZIP: 20850 FORMER COMPANY: FORMER CONFORMED NAME: ADEONA PHARMACEUTICALS, INC. DATE OF NAME CHANGE: 20081027 FORMER COMPANY: FORMER CONFORMED NAME: PIPEX PHARMACEUTICALS, INC. DATE OF NAME CHANGE: 20061214 FORMER COMPANY: FORMER CONFORMED NAME: SHEFFIELD PHARMACEUTICALS INC DATE OF NAME CHANGE: 19970730 8-K/A 1 tm2225124d1_8ka.htm FORM 8-K/A
0000894158 true As previously reported by Synthetic Biologics, Inc. the ("Company") in a Current Report on Form 8-K filed by the Company with the Securities and Exchange Commission (the "SEC") on March 11, 2022 (the "Initial Form 8-K"), the Company closed on March 10, 2022 the previously announced acquisiton (the "Acquisition") of all of the outstanding shares of VCN Biosciences, S.L., a corporation organized under the laws of Spain ("VCN"). On May 6, 2022, the Company filed Amendment No. 1 to the Initial From 8-K to provide the audited financial statements of VCN as of and for the fiscal year ended December 31, 2021 and unaudited pro forma condensed combined financial statements of the Company reflecting the Acquisiton of VCN as of and for the year ended December 31, 2021. This Amendment No. 2 is being filed to include unaudited pro forma condensed combined financial statements of the Company reflecting the Acquisition of VCN as of and for the six months ended June 30, 2022. 0000894158 2022-09-06 2022-09-06 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K/A

 

AMENDMENT NO. 2
TO
CURRENT REPORT

 

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): September 6, 2022

 

SYNTHETIC BIOLOGICS, INC.

(Exact name of registrant as specified in its charter)

 

Nevada   001-12584   13-3808303

(State or other jurisdiction of

incorporation)

   (Commission File No.)  

(IRS Employer Identification

No.)

 

9605 Medical Center Drive, Suite 270

Rockville, Maryland 20850

(Address of principal executive offices and zip code)

 

(301) 417-4364

Registrant’s telephone number, including area code

 

N/A

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

  ¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

  ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

  ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

  ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class Trading Symbol(s) Name of each exchange on which
registered
Common stock, par value $0.001 per share SYN NYSE American

 

Indicate by check mark whether the registrant is an emerging growth company as defined in in Rule 405 of the Securities Act of 1933 (17 CFR §230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2 of this chapter).

 

Emerging growth company ¨

 

If an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

 

 

  

Introductory Note

 

As previously reported by Synthetic Biologics, Inc. the (“Company”) in a Current Report on Form 8-K filed by the Company with the Securities and Exchange Commission (the “SEC”) on March 11, 2022 (the “Initial Form 8-K”), the Company closed on March 10, 2022 the previously announced acquisition (the “Acquisition”) of all of the outstanding shares of VCN Biosciences, S.L., a corporation organized under the laws of Spain (“VCN”).

 

On May 6, 2022, the Company filed Amendment No. 1 to the Initial From 8-K to provide the audited financial statements of VCN as of and for the fiscal year ended December 31, 2021 and unaudited pro forma condensed combined financial statements of the Company reflecting the Acquisiton of VCN as of and for the year ended December 31, 2021. This Amendment No. 2 is being filed to include unaudited pro forma condensed combined financial statements of the Company reflecting the Acquisition of VCN as of and for the six months ended June 30, 2022.

 

 

 

 

Item 9.01.   Financial Statements and Exhibits

 

(a) Financial Statements of Businesses Acquired

 

VCN’s audited financial statements as of and for the year ended December 31, 2021 required by Item 9.01(a) of Form 8-K are filed herewith as Exhibit 99.1 and incorporated by reference in this Item 9.01(a).

 

(b) Unaudited Pro Forma Financial Information

 

The pro forma condensed combined financial information of the Company as of and for the year ended December 31, 2021 required by Item 9.01(b) of Form 8-K is filed herewith as Exhibit 99.2 and incorporated by reference in this Item 9.01(b).

 

The pro forma condensed combined financial information of the Company as of and for the six months ended June 30, 2022 required by Item 9.01(b) of Form 8-K is filed herewith as Exhibit 99.3 and incorporated by reference in this Item 9.01(b).

 

(d) Exhibits.

 

The following exhibits are filed with this Amendment No. 2 to Current Report on Form 8-K/A.

 

Exhibit
Number		   Description
     
2.1*   Share Purchase Agreement, by and among Synthetic Biologics, Inc., VCN Biosciences, S.L. and the shareholders of VCN Biosciences, S.L., dated December 14, 2021 (incorporated by reference to the Form 8-K filed with the Securities and Exchange Commission on December 14, 2021 (File No. 001-12584)
     
2.2*   Amendment, dated March 9, 2022, to the Share Purchase Agreement, by and among Synthetic Biologics, Inc., VCN Biosciences, S.L. and the shareholders of VCN Biosciences, S.L., dated December 14, 2021 (incorporated by reference to the Form 8-K filed with the Securities and Exchange Commission on March 11, 2022 (File No. 001-12584)  
     
23.1*   Consent of of KPMG Auditores, S.L. independent auditor  (incorporated by reference to the Form 8-K filed with the Securities and Exchange Commission on May 6, 2022 (File No. 001-12584)
     
99.1*   VCN Biosciences, S.L. audited financial statements as of and for the year ended December 31, 2021 (incorporated by reference to the Form 8-K filed with the Securities and Exchange Commission on May 6, 2022 (File No. 001-12584)
     
99.2*   Synthetic Biologics, Inc. and Subsidiaries Unaudited Pro Forma Condensed Combined Financial Statements as of and for the year ended December 31, 2021 (incorporated by reference to the Form 8-K filed with the Securities and Exchange Commission on May 6, 2022 (File No. 001-12584)
     
99.3   Synthetic Biologics, Inc. and Subsidiaries Unaudited Pro Forma Condensed Combined Financial Statements for the six months ended June 30, 2022
     
104   Cover Page Interactive Data File (embedded within the XBRL document)

 

 * Previously filed.

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Amendment No. 2 to Current Report on Form 8-K/A to be signed on its behalf by the undersigned hereunto duly authorized.

 

Dated: September 6, 2022 SYNTHETIC BIOLOGICS, INC.
       
  By: /s/ Steven A. Shallcross
    Name:  Steven A. Shallcross
    Title:

Chief Executive Officer

and Chief Financial Officer

 

 

 

 EX-99.3 2 tm2225124d1_ex99-3.htm EXHIBIT 99.3

 

Exhibit 99.3

 

UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION

 

On December 14, 2021, Synthetic Biologics, Inc. (the “Company” or the “Buyer”) entered into a Share Purchase Agreement (the “Agreement” or “SPA”) with VCN Biosciences, S.L. (“VCN”) and each of VCN’s shareholders (the “Sellers ”) pursuant to which the Company would purchase 100% of VCN’s capital stock in exchange for total consideration consisting of $4.7 million (the “Closing Cash Consideration”), 2,639,531 of shares of the Company’s common stock (equal to 19.99% of outstanding shares of common stock on the Closing Date) (the “Closing Shares”) and certain contingent milestone payments of up to $70.25 million payable in cash (the “Milestone Payments” and, collectively with the Closing Cash Consideration and the Closing Shares, the “Total Consideration”). The transaction is hereinafter referred to as the “Acquisition.” The Acquisition closed on March 10, 2022 (the “Closing” or the “Closing Date”).

 

VCN is a private limited company founded in Spain in 2009 and is headquartered in Barcelona. VCN’s operations consist primarily of research and development activities with respect to certain biotechnologies and VCN is in its early stages of development. The Acquisition is legally structured pursuant to Spanish law to result in the tax-free purchase of shares. After the Closing (as defined below), VCN continued its current legal structure as a private limited company (sociedad limitada) formed under the laws of Spain and became a wholly owned subsidiary of Company.

 

The following unaudited pro forma condensed combined statement of operations for the six months ended June 30, 2022 are based on the historical audited financial statements of the Company and VCN. The unaudited pro forma condensed combined statement of operations for the six months ended June 30, 2022 gives effect to the Acquisition as if it had occurred on January 1, 2022. The unaudited pro forma condensed balance sheet as of June 30, 2022 is not required since VCN's results for that period are included in the Company's consolidated balance sheet as of that date. The unaudited pro forma statement of operations for the year ended December 31, 2021 was filed in the Company's Current Report on Form 8-K/A on May 6, 2022.

 

The unaudited pro forma combined financial statements do not necessarily reflect what the combined company’s financial condition or results of operations would have been had the Acquisition occurred on the dates indicated. They also may not be useful in predicting the future financial condition and results of operations of the combined company. The combined company’s actual financial condition and results of operations may differ significantly from the pro forma amounts reflected herein due to a variety of factors.

 

The unaudited pro forma combined financial information herein has been adjusted to depict the accounting of a business combination for the Acquisition (“Transaction Accounting Adjustments”), which reflect the application of the purchase accounting required by U.S. GAAP and SEC rules and regulations, linking the effects of the Acquisition to the historical consolidated financial statements. The unaudited pro forma combined financial information does not present any synergies and other transaction effects that have occurred or are expected to occur (“Management’s Adjustments”) and only presents Transaction Accounting Adjustments. The unaudited pro forma condensed combined financial statements reflect management’s preliminary and best estimate of the fair value of the tangible and intangible assets acquired and liabilities assumed in the Acquisition based on information currently available. Certain valuations and studies necessary to finalize the determination of estimated fair values and estimated useful lives, are incomplete as of the date of this filing. As final valuations are performed, increases or decreases in the unaudited pro forma condensed combined fair value of assets acquired and liabilities assumed may result in adjustments, which may be material, to the balance sheet and/or statements of operations.

 

Certain reclassifications and adjustments were made to VCN’s historical financial statements to conform them to generally accepted accounting principles in the U.S., reclassify VCN’s financial statement presentation to align them with the Company’s presentation, and to translate VCN’s reporting currency (the Euro) to the Company’s reporting currency (the U.S. dollar).

 

 

 

 

   Synthetic Biologics, Inc.
Unaudited Pro Forma Statement of Operations
For the year ended June 30, 2022
(Amounts in thousands)		     
                         
   Synthetic
Biologics, Inc.
Historical		   VCN Biosciences,
S.L. Historical
January 1, 2022 -
March 9, 2022		   Reclassifications
and Basis of Accounting
Adjustments (VCN)
Note 3		   Translation of VCN
Historical Financial
Statements to USD
Reporting Currency		   Transaction
Accounting
Adjustments		   Pro Forma
Combined		 
Operating expenses                              
General and administrative  $3,155   €208   €-   $235        $3,390 
Research and development   6,082    627    (378)(1)   281    -    6,363 
Total operating expenses   9,237    835    (378)   516    -    9,753 
                               
Operating loss   (9,237)   (835)   378    (516)   -    (9,753)
                               
Other income (expense)                              
Interest and other income   (31)   8    -    9         (22)
Interest and other expense   27    (15)   -    (17)        10 
Total other income (expense)   (4)   (7)   -    (8)   -    (12)
                               
Provision (benefit) for income taxes   -    -    -    -         - 
                               
Net loss  $(9,241)  €(842)  €378   $(524)  $-   $(9,765)
                               
Net Loss Attributable to Non-controlling Interest   -              -         - 
Net Loss Attributable to Synthetic Biologics, Inc.   (9,241)   (842)   378    (524)   -    (9,765)
                               
Effect of Series A Preferred Stock Price Adjustment   -    -    -    -         - 
Series A and B Preferred Stock Dividends   -    -    -    -         - 
Net Loss Attributable to Common Stockholders  $(9,241)  $(842)  $378   $(524)  $-   $(9,765)
                               
Net loss per common share - basic and diluted  $0.62                       $(0.00)
Weighted average shares outstanding - basic and diluted   14,837,832                        14,837,832 
                               
Net Loss   (9,241)                       (9,765)
Loss on foreign currency translation   (1,317)                       (1,317)
Total comprehensive loss   (10,558)                       (11,082)
Comprehensive loss attributable to non-controlling interest   -                        - 
Comprehensive loss attributable to Synthetic Biologics, Inc. and Subsidiaries  $(10,558)                      $(11,082)

  

 

 

 

NOTES TO UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL STATEMENTS

 

1.Description of Transaction

 

On December 14, 2021, Synthetic Biologics, Inc. (the “Company” or the “Buyer”) entered into a Share Purchase Agreement (the “Agreement” or “SPA”) with VCN Biosciences, S.L. (“VCN”) and each of VCN’s shareholders (the “Sellers ”) pursuant to which the Company would purchase 100% of VCN’s capital stock in exchange for total consideration consisting of $4.7 million (the “Closing Cash Consideration”), 26,395,303 of shares of the Company’s common stock (equal to 19.99% of outstanding shares of common stock on the Closing Date) (the “Closing Shares”) and certain contingent milestone payments of up to $70.25 million payable in cash (the “Milestone Payments” and, collectively with the Closing Cash Consideration and the Closing Shares, the “Total Consideration”). The transaction is hereinafter referred to as the “Acquisition.” The Acquisition closed on March 10, 2022 (the “Closing” or the “Closing Date”).

 

VCN is a private limited company founded in Spain in 2009 and is headquartered in Barcelona. VCN’s operations consist primarily of research and development activities with respect to certain biotechnologies and VCN is in its early stages of development. The Acquisition is legally structured pursuant to Spanish law to result in the tax-free purchase of shares. After the Closing (as defined below), VCN continued its current legal structure as a private limited company (sociedad limitada) formed under the laws of Spain and became a wholly owned subsidiary of Company.

 

2.Basis of Presentation

 

The unaudited pro forma condensed combined financial statements were prepared in accordance with generally accepted accounting principles in the United States (“U.S. GAAP”) and the regulations of the U.S. Securities and Exchange Commission (the “SEC”) and are intended to show how the Acquisition might have affected the historical financial statements if the Acquisition had been completed on January 1, 2022 for the purpose of the statement of operations for the six months ended June 30, 2022.

 

The Acquisition will be accounted for as a business combination, with the Company treated as the “acquirer” and VCN treated as the “acquired” company for financial reporting purposes. Under the acquisition method of accounting, the total estimated purchase price of an acquisition allocated to the net tangible and intangible assets is based on their estimated fair values. Such valuations are based on available information and certain assumptions that management believes are reasonable. The preliminary allocation of the purchase price to the tangible and intangible

assets acquired and liabilities assumed is based on various preliminary estimates. Accordingly, the pro forma adjustments are preliminary and have been made solely for the purpose of providing this unaudited pro forma combined financial information. Differences between these preliminary estimates and the final acquisition accounting may occur and these differences could be material. The differences, if any, could have a material impact on the accompanying unaudited pro forma condensed combined financial information and the Company’s future results of operations and financial position.

 

The unaudited pro forma condensed combined financial information includes certain reclassifications to conform the historical financial statement presentation of VCN to the Company. See “Note 3 – Reclassifications and Conforming Basis Adjustments” herein for additional information on the reclassifications.

 

Certain disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted in these unaudited pro forma condensed combined financial statements as permitted by SEC rules and regulations.

 

 

 

 

3.Reclassifications and Conforming Basis Adjustments

 

An adjustment is presented in the accompanying pro forma financial statements, as follows:

 

(1)To adjust research and development expense for the settlement of pre-existing loan expensed by Grifols which is accounted for as part of GAAP purchase consideration

 

All VCN statement of operations amounts have been translated into the Company’s U.S. dollar reporting currency using the average exchange rates for the six months ended June 30, 2022.

 

There are no Transaction Accounting Adjustments required for the six months ended June 30, 2022.

 

4.Net Loss Per Share

 

Pro forma net loss attributable to common stockholders as originally reported for the six month ended June 30,2022 is adjusted for the pro forma impacts of the Acquisition. Basic and diluted weighted average shares outstanding as originally reported are adjusted to reflect the effects of the issuance of 2,639,531 shares of common stock to the Sellers as of January 1, 2022.

 

 

 

 EX-101.SCH 3 syn-20220906.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 syn-20220906_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 syn-20220906_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 6 R1.htm IDEA: XBRL DOCUMENT v3.22.2.2
Cover
Sep. 06, 2022
Cover [Abstract]  
Document Type 8-K/A
Amendment Flag true
Amendment Description As previously reported by Synthetic Biologics, Inc. the ("Company") in a Current Report on Form 8-K filed by the Company with the Securities and Exchange Commission (the "SEC") on March 11, 2022 (the "Initial Form 8-K"), the Company closed on March 10, 2022 the previously announced acquisiton (the "Acquisition") of all of the outstanding shares of VCN Biosciences, S.L., a corporation organized under the laws of Spain ("VCN"). On May 6, 2022, the Company filed Amendment No. 1 to the Initial From 8-K to provide the audited financial statements of VCN as of and for the fiscal year ended December 31, 2021 and unaudited pro forma condensed combined financial statements of the Company reflecting the Acquisiton of VCN as of and for the year ended December 31, 2021. This Amendment No. 2 is being filed to include unaudited pro forma condensed combined financial statements of the Company reflecting the Acquisition of VCN as of and for the six months ended June 30, 2022.
Document Period End Date Sep. 06, 2022
Entity File Number 001-12584
Entity Registrant Name SYNTHETIC BIOLOGICS, INC.
Entity Central Index Key 0000894158
Entity Tax Identification Number 13-3808303
Entity Incorporation, State or Country Code NV
Entity Address, Address Line One 9605 Medical Center Drive
Entity Address, Address Line Two Suite 270
Entity Address, City or Town Rockville
Entity Address, State or Province MD
Entity Address, Postal Zip Code 20850
City Area Code 301
Local Phone Number 417-4364
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common stock, par value $0.001 per share
Trading Symbol SYN
Security Exchange Name NYSEAMER
Entity Emerging Growth Company false
XML 7 tm2225124d1_8ka_htm.xml IDEA: XBRL DOCUMENT 0000894158 2022-09-06 2022-09-06 iso4217:USD shares iso4217:USD shares 0000894158 true As previously reported by Synthetic Biologics, Inc. the ("Company") in a Current Report on Form 8-K filed by the Company with the Securities and Exchange Commission (the "SEC") on March 11, 2022 (the "Initial Form 8-K"), the Company closed on March 10, 2022 the previously announced acquisiton (the "Acquisition") of all of the outstanding shares of VCN Biosciences, S.L., a corporation organized under the laws of Spain ("VCN"). On May 6, 2022, the Company filed Amendment No. 1 to the Initial From 8-K to provide the audited financial statements of VCN as of and for the fiscal year ended December 31, 2021 and unaudited pro forma condensed combined financial statements of the Company reflecting the Acquisiton of VCN as of and for the year ended December 31, 2021. This Amendment No. 2 is being filed to include unaudited pro forma condensed combined financial statements of the Company reflecting the Acquisition of VCN as of and for the six months ended June 30, 2022. 8-K/A 2022-09-06 SYNTHETIC BIOLOGICS, INC. NV 001-12584 13-3808303 9605 Medical Center Drive Suite 270 Rockville MD 20850 301 417-4364 false false false false Common stock, par value $0.001 per share SYN NYSEAMER false EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2.2 html 1 24 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://syntheticbiologics.com/role/Cover Cover Cover 1 false false All Reports Book All Reports tm2225124d1_8ka.htm syn-20220906.xsd syn-20220906_lab.xml syn-20220906_pre.xml tm2225124d1_ex99-3.htm http://xbrl.sec.gov/dei/2021q4 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "tm2225124d1_8ka.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "tm2225124d1_8ka.htm" ] }, "labelLink": { "local": [ "syn-20220906_lab.xml" ] }, "presentationLink": { "local": [ "syn-20220906_pre.xml" ] }, "schema": { "local": [ "syn-20220906.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021q4": 3, "total": 3 }, "keyCustom": 0, "keyStandard": 24, "memberCustom": 0, "memberStandard": 0, "nsprefix": "syn", "nsuri": "http://syntheticbiologics.com/20220906", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm2225124d1_8ka.htm", "contextRef": "From2022-09-06to2022-09-06", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://syntheticbiologics.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm2225124d1_8ka.htm", "contextRef": "From2022-09-06to2022-09-06", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" } }, "version": "2.1" } ZIP 14 0001104659-22-097870-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-22-097870-xbrl.zip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end